Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
51 participants
OBSERVATIONAL
2013-04-30
2018-04-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Cell Dysfunction in Severe Alcoholic Hepatitis
NCT02275195
Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease
NCT00610597
Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis
NCT03711669
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis
NCT00160940
Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses
NCT00001257
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alcoholic hepatitis
Patients with alcoholic hepatic; cases.
No interventions assigned to this group
Healthy controls
Persons undergoing hepatic resection; controls.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* relevant history of alcohol consumption (\>40g/day for a minimum of 6 months with cessation of consumption no earlier than 3 months prior to admission)
* bilirubin \> 80 mol/l
* neutrophil granulocytes \> 10x10\^9/L
* exclusion of other liver pathology including biliary disease
* histological verification on liver biopsy
* Written, informed consent
Exclusion Criteria
* Severe, acute bacterial infection (peritonitis, sepsis, pneumonia, urinary tract infection etc.)
* Cancer
* Prednisolon or pentoxifylline treatment within the past 8 weeks
* Pregnancy
18 Years
69 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sidsel Støy, Phd student
Role: PRINCIPAL_INVESTIGATOR
Department of hepatology and gastroenterology, Aarhus University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Hepatology and gastroenterology V, Aarhus university hospital
Aarhus, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUH
Identifier Type: OTHER
Identifier Source: secondary_id
AHIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.